spesolimab-sbzo

CHEBI:CHEBI_749454

Drug Classification

Important Medical Information

⚕️ This information is sourced from ChEBI (Chemical Entities of Biological Interest) database and is intended for educational purposes only.

  • Always consult with a healthcare professional before starting, stopping, or modifying any medication.
  • Side effects may vary and this list may not be comprehensive.
  • Drug interactions may occur with other medications.

Additional Identifiers

🔍 Click on any linked disease name to learn more about the conditions this medication is used to treat, or explore related drug classifications for more information about similar medications.

Additional Attributes

rxcui
2678984
brand_name
SPEVIGO
brand_name_base
SPEVIGO
product_type
HUMAN PRESCRIPTION DRUG
listing_expiration_date
20251231
dosage_form
INJECTION
active_ingredient_strength
150 mg/mL
route
INTRAVENOUS
marketing_start_date
20220901
package_marketing_start_date
20220901
marketing_category
BLA
labeler_name
Boehringer Ingelheim Pharmaceuticals, Inc.
manufacturer_name
Boehringer Ingelheim Pharmaceuticals, Inc.
generic_name
spesolimab-sbzo
product_ndc
0597-0620
application_number
BLA761244
spl_id
58430516-81db-410b-94e0-42870b8194ca
active_ingredient_name
SPESOLIMAB
package_ndc
0597-0620-20
package_description
2 SYRINGE in 1 CARTON (0597-0620-20) / 150 mL in 1 SYRINGE
unii
5IB2J79MCX
spl_set_id
41a481ee-3062-45d1-aed5-17e8b105634d
nui
N0000194040
pharm_class_epc
Interleukin-36 Receptor Antagonist [EPC]
pharm_class
Interleukin-36 Receptor Antagonists [MoA]
pharm_class_moa
Interleukin-36 Receptor Antagonists [MoA]
22-rdf-syntax-ns#type
http://www.w3.org/2002/07/owl#Class